AML
News
Treatment may allow HSCT without radiation, chemotherapy
Key clinical point: A new treatment allowed hematopoietic stem cell engraftment in immunocompetent mice without the need for toxic preconditioning...
News
Venetoclax can produce short-term responses in AML
Results of a phase 2 trial suggest the BCL2 inhibitor venetoclax can produce responses in patients with acute myelogenous leukemia (AML) who do...
News
HDAC inhibitor granted breakthrough designation
Image by Eric Smith The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for the histone deacetylase (HDAC)...
News
Radiologists no longer have higher risk of cancer-related death
Photo by Rhoda Baer Radiologists who graduated from medical school after 1940 do not have an increased risk of dying from radiation-related...
News
Antimalarials, antifungals may fight leukemia
A new study has shed light on the process leukemia cells use to evade apoptosis and revealed drugs that can fight this process. Investigators...
News
Predicting outcomes in AML patients
Photo by Darren Baker An international competition has produced models that can help predict outcomes in patients with acute myeloid leukemia (...
News
Immunotherapy may benefit relapsed HSCT recipients
Photo from Business Wire Results of a phase 1 study suggest that repeated doses of the immunotherapy drug ipilimumab is a feasible treatment...
News
Cell of origin impacts aggressiveness of AML
New research suggests the cell of origin controls the aggressiveness and outcome of acute myeloid leukemia (AML) driven by MLL-AF9. Using a mouse...
News
Ipilimumab may restore antitumor immunity after relapse from HSCT
Key clinical point: Anti-CTLA-4 therapy may restore graft-versus-tumor effect in patients with hematologic malignancies relapsed after allogeneic...
News
ATRA-arsenic ‘new standard of care’ for APL
Key clinical point: ATRA-ATO was superior to ATRA-chemotherapy as first-line therapy for acute promyelocytic leukemia. Major finding: Event-free...
News
Method reveals cells of origin in AML
in the bone marrow Whole-genome profiling of open chromatin is a reliable way to identify the cells of origin in acute myeloid leukemia (AML),...